Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia

Trial Profile

Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders
  • Focus Therapeutic Use
  • Acronyms JET8
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Mar 2018 Primary endpoint (Improvement of sleep time during the first night of a phase advance) has been met, according to a Vanda Pharmaceuticals media release.
    • 05 Mar 2018 Results presented in a Vanda Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top